Compare · GLTO vs NVO
GLTO vs NVO
Side-by-side comparison of Galecto Inc. (GLTO) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GLTO and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $187.53B, about 3270.2x GLTO ($57.3M).
- Over the past year, GLTO is up 785.8% and NVO is down 41.7% - GLTO leads by 827.5 points.
- NVO has hit the wire 11 times in the past 4 weeks while GLTO has been quiet.
- NVO has more recent analyst coverage (25 ratings vs 4 for GLTO).
- Company
- Galecto Inc.
- Novo Nordisk A/S
- Price
- $28.17-2.07%
- $42.01-2.10%
- Market cap
- $57.3M
- $187.53B
- 1M return
- +27.35%
- -5.38%
- 1Y return
- +785.85%
- -41.69%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2020
- News (4w)
- 0
- 11
- Recent ratings
- 4
- 25
Galecto Inc.
Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung. Its products also comprise GB2064, which is in Phase I/IIa for the treatment of myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase I/IIa for the treatment of cancer and fibrosis. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest GLTO
- Galecto Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits
- Galecto Announces Name Change to Damora Therapeutics with Mission to Fundamentally Redefine Care for Patients with Blood Disorders
- Amendment: SEC Form SCHEDULE 13G/A filed by Galecto Inc.
- Galecto Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Galecto to Participate in Leerink Partners 2026 Global Healthcare Conference
- SEC Form SCHEDULE 13G filed by Galecto Inc.
- UBS initiated coverage on Galecto with a new price target
- Galecto Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $316.3 Million
- Director Bruno Julianne converted options into 129,000 shares, increasing direct ownership by 1,606% to 137,032 units (SEC Form 4)
- Director Fairmount Funds Management Llc converted options into 8,713,000 shares (SEC Form 4)
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care
- Peptide Wellness Market Could Near $300 Billion as Consumer Demand Accelerates